Ligand Pharmaceuticals Hits New 52-Week High at $300.09

Ligand Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 300.09 on June 25, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, where it has demonstrated remarkable growth over the past year, with a staggering 272.09% increase compared to the S&P 500's 20.77% performance. With a market capitalization of USD 3,898 million, Ligand Pharmaceuticals is classified as a small-cap company. The firm has shown robust financial health, being net-debt free and reporting impressive operating cash flow of USD 123.57 million. Additionally, the company has consistently delivered positive results over the last three consecutive quarters, including a notable net profit of USD 36.68 million, reflecting a growth rate of 157.25%. Ligand's return on equity stands at 5.61%, complemented by a price-to-book ratio of 3.83, indicating an attractive valuation. The stock's performance has not only outpaced the broader market but has also garnered high institutional holdings, suggesting strong confidence in its fundamentals.